Perrott J, Murphy NG, Zed PJ
One study found that exenatide, a GLP-1 agonist that was approved to treat Type 2 diabetes back in 2005, significantly reduced the alcohol-cue reactivity in the area of the brain related to drug reward and addiction and significantly reduced the total alcohol intake in patients with obesity in particular
Abandoning titration principles Split dosing does not eliminate the need for gradual dose escalation
At standard low doses used for diabetes, the pill often results in less weight loss than the high-dose injections
Together, these findings necessitate further investigations to ascertain whether coordinated inhibition of NMDA receptors in GLP-1 receptor neurons modulates neuronal activity beyond canonical feeding regions, such as the mesolimbic dopaminergic reward pathway
Then we scoured the glutathione supplement market to identify products whose qualities aligned with what we'd found in our research